Table 2.

Clinicopathologic characteristics of patients with NSCLC (n = 1,328)

FGFR fusionEGFR Mut. (positive)KRAS Mut. (positive)HER2 Mut. (positive)BRAF Mut. (positive)FGFR (negative)
CharacteristicPatients, n (%)Patients, n (%)PPatients, n (%)PPatients, n (%)PPatients, n (%)PPatients, n (%)P
Age, y
 ≤608 (47.1)296 (47.5)44 (55.0)19 (73.1)4 (33.3)625 (47.7)
 >609 (52.9)327 (52.5)0.97136 (45.0)0.5517 (26.9)0.0848 (66.7)0.703686 (52.3)0.960
Sex
 Male16 (94.1)232 (37.2)65 (81.3)3 (11.5)8 (66.7)738 (56.3)
 Female1 (5.9)391 (62.8)<0.00115 (18.8)0.29023 (88.5)<0.0014 (33.3)0.130573 (43.7)0.002
Smoking status
 Never1 (5.9)496 (79.6)23 (28.8)25 (96.2)4 (33.3)746 (56.9)
 Smoker16 (94.1)127 (20.4)<0.00157 (71.3)0.3571 (3.8)<0.0018 (66.7)0.198565 (43.1)<0.001
Histology
 AD6 (35.3)609 (97.8)73 (91.3)25 (96.2)12 (100.0)1010 (77.0)
 SCC11 (64.7)14 (2.2)<0.0017 (8.8)<0.0011 (3.8)<0.0010 (0.0)<0.001301 (23.0)<0.001
Tumor size
 ≤3 cm2 (11.8)480 (77.0)50 (62.5)18 (69.2)7 (58.3)830 (63.3)
 >3 cm15 (88.2)143 (23.0)<0.00130 (37.5)0.0018 (30.8)<0.0015 (41.7)0.14481 (36.7)<0.001
Stage
 I–II13 (76.5)434 (69.7)57 (71.3)17 (65.4)8 (66.7)893 (68.1)
 III–IV4 (23.5)189 (30.3)0.54623 (28.8)0.7739 (34.6)0.4394 (33.3)0.683418 (31.9)0.462
Differentiation
 Well-moderate8 (47.1)481 (77.2)49 (61.3)18 (69.2)8 (66.7)870 (66.4)
 Poor9 (53.9)142 (22.8)0.00831 (38.8)0.2808 (30.8)0.1464 (33.3)0.296441 (33.6)0.095

NOTE: The bold values indicate that the differences are statistically significant.

Abbreviation: AD, adenocarcinoma.